ALSUntangled #67: rituximab.
Publication
, Journal Article
Li, X; Armon, C; Barkhaus, P; Barnes, B; Benatar, M; Bertorini, T; Bromberg, M; Carter, GT; Crayle, J; Cudkowicz, M; Dimachkie, M; Feldman, EL ...
Published in: Amyotroph Lateral Scler Frontotemporal Degener
August 2023
ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Amyotroph Lateral Scler Frontotemporal Degener
DOI
EISSN
2167-9223
Publication Date
August 2023
Volume
24
Issue
5-6
Start / End Page
544 / 547
Location
England
Related Subject Headings
- Rituximab
- Off-Label Use
- Humans
- Amyotrophic Lateral Sclerosis
- 3209 Neurosciences
- 1109 Neurosciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Li, X., Armon, C., Barkhaus, P., Barnes, B., Benatar, M., Bertorini, T., … Bedlack, R. (2023). ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener, 24(5–6), 544–547. https://doi.org/10.1080/21678421.2022.2122845
Li, Xiaoyan, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, et al. “ALSUntangled #67: rituximab.” Amyotroph Lateral Scler Frontotemporal Degener 24, no. 5–6 (August 2023): 544–47. https://doi.org/10.1080/21678421.2022.2122845.
Li X, Armon C, Barkhaus P, Barnes B, Benatar M, Bertorini T, et al. ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5–6):544–7.
Li, Xiaoyan, et al. “ALSUntangled #67: rituximab.” Amyotroph Lateral Scler Frontotemporal Degener, vol. 24, no. 5–6, Aug. 2023, pp. 544–47. Pubmed, doi:10.1080/21678421.2022.2122845.
Li X, Armon C, Barkhaus P, Barnes B, Benatar M, Bertorini T, Bromberg M, Carter GT, Crayle J, Cudkowicz M, Dimachkie M, Feldman EL, Glass J, Goslinga J, Heiman-Patterson T, Jhooty S, Lichtenstein R, Lund I, Mcdermott C, Pattee G, Pierce K, Ratner D, Salmon K, Wicks P, Bedlack R. ALSUntangled #67: rituximab. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5–6):544–547.
Published In
Amyotroph Lateral Scler Frontotemporal Degener
DOI
EISSN
2167-9223
Publication Date
August 2023
Volume
24
Issue
5-6
Start / End Page
544 / 547
Location
England
Related Subject Headings
- Rituximab
- Off-Label Use
- Humans
- Amyotrophic Lateral Sclerosis
- 3209 Neurosciences
- 1109 Neurosciences
- 1103 Clinical Sciences